Analyst firms · BofA Securities · SR
BofA Securities SR price target and rating history
Spire Inc. (SR) · Utilities
BofA Securities rates Spire Inc. (SR) Neutral with a $89 price target, as of its latest action on Oct 29, 2025. It has published 7 rating actions on SR since November 2021, including 2 upgrades and 4 downgrades. Across 6 firms with a SR price target in the last 12 months, the median target is $92.50.
- Current rating
- Neutral
- Price target
- $89
- Median target, all firms
- $92.50
- Actions on SR
- 7
BofA Securities price target on SR
Every BofA Securities rating on SR
- Oct 29, 2025
- Aug 15, 2025
- Dec 13, 2024
- Dec 12, 2022
- Apr 18, 2022
- Nov 23, 2021
- Nov 8, 2021
How other firms rate SR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Scotiabank | Sector Perform | $79 | Sep 29, 2026 |
| Huntington | Outperform | $93 | Sep 14, 2026 |
| Mizuho | Outperform | $88 | Jul 7, 2026 |
| Wolfe Research | Peer Perform | May 26, 2026 | |
| Wells Fargo | Overweight | $96 | May 12, 2026 |
| TD Cowen | Hold | $101 | Apr 17, 2026 |
| Morgan Stanley | Overweight | $92 | Dec 16, 2025 |
Questions about BofA Securities and SR
- What is BofA Securities's price target for SR?
- BofA Securities's latest stated price target for Spire Inc. (SR) is $89, from its action on Oct 29, 2025.
- What is BofA Securities's rating on SR?
- BofA Securities rates SR Neutral, a neutral rating, as of Oct 29, 2025.
- When did BofA Securities last change its view on SR?
- On Oct 29, 2025, BofA Securities upgrades to Neutral from Underperform, price target $89.
- How does BofA Securities's SR target compare with other analysts?
- Across 6 firms with a SR price target in the last 12 months, the median target is $92.50.
More SR rating histories
All BofA Securities ratingsSR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.